Chemotherapy – University of Chicago Medical Center – USA

Survival:4.7 months
Toxicity Grade:5
Country:United States
City/State/Province:Chicago, Illinois
Hospital:University of Chicago Medical Center


Patients: This Phase II study involved 17 patients with malignant mesothelioma.

Treatment: The treatment consisted of the chemotherapy drug, gemcitabine.

Toxicity: Two patients died without documentation of progressive disease and at least one of these deaths was considered related to drug toxicity and disease progression. In addition, grade 3-4 toxicities included hematologic, infection, dyspnea, edema, malaise/fatigue, cerebellar, cardiac dysrhythmia, and hyponatremia.

Results: There were no complete or partial responses and the median survival time was 4.7 months.

Correspondence: Hedy L. Kindler, MD

Get your free copy of
“Surviving Mesothelioma” Today!